{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivastigmine&page=2",
    "query": {
      "intervention": "Rivastigmine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivastigmine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T20:33:12.226Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00305903",
      "title": "Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rivastigmine, memantine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 150,
      "start_date": "2006-03",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2007-12-21",
      "last_synced_at": "2026-09-27T20:33:12.226Z",
      "location_count": 1,
      "location_summary": "Paterson, New Jersey",
      "locations": [
        {
          "city": "Paterson",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00305903"
    },
    {
      "nct_id": "NCT00158210",
      "title": "Rivastigmine For Methamphetamine Dependent Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Substance-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Rivastigmine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2006-05",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-09-27T20:33:12.226Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00158210"
    },
    {
      "nct_id": "NCT00104442",
      "title": "Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rivastigmine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 80,
      "start_date": "2003-10",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2007-12-21",
      "last_synced_at": "2026-09-27T20:33:12.226Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104442"
    },
    {
      "nct_id": "NCT06382649",
      "title": "Rivastigmine for Antimuscarinic Delirium",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anticholinergic Toxicity"
      ],
      "interventions": [
        {
          "name": "Rivastigmine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2026-06",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-27T20:33:12.226Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06382649"
    },
    {
      "nct_id": "NCT01670526",
      "title": "Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Traumatic Brain Injury",
        "Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Rivastigmine Transdermal Patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 94,
      "start_date": "2012-12",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-09-27T20:33:12.226Z",
      "location_count": 8,
      "location_summary": "San Diego, California • Miami, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Hines",
          "state": "Illinois"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670526"
    },
    {
      "nct_id": "NCT01951118",
      "title": "Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Mild Cognitive Impairment",
        "Delirium, Dementia, Amnestic, Cognitive Disorders"
      ],
      "interventions": [
        {
          "name": "Donepezil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "55 Years to 95 Years"
      },
      "enrollment_count": 121,
      "start_date": "2013-10",
      "completion_date": "2019-05",
      "has_results": true,
      "last_update_posted_date": "2020-07-13",
      "last_synced_at": "2026-09-27T20:33:12.226Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951118"
    },
    {
      "nct_id": "NCT04731311",
      "title": "Telerehabilitation Alzheimer's Disease Usability (TADU)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Healthy Aging"
      ],
      "interventions": [
        {
          "name": "Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Bright Cloud International Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "65 Years to 85 Years"
      },
      "enrollment_count": 4,
      "start_date": "2021-07-29",
      "completion_date": "2021-09-07",
      "has_results": false,
      "last_update_posted_date": "2022-04-27",
      "last_synced_at": "2026-09-27T20:33:12.226Z",
      "location_count": 1,
      "location_summary": "North Brunswick, New Jersey",
      "locations": [
        {
          "city": "North Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04731311"
    },
    {
      "nct_id": "NCT00623103",
      "title": "Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease Dementia"
      ],
      "interventions": [
        {
          "name": "Rivastigmine capsule",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 583,
      "start_date": "2008-01",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2011-11-28",
      "last_synced_at": "2026-09-27T20:33:12.226Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Reseda",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623103"
    },
    {
      "nct_id": "NCT00018278",
      "title": "Electrophysiologic Measures of Treatment Response in Alzheimer Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Aricept",
          "type": "DRUG"
        },
        {
          "name": "Exelon",
          "type": "DRUG"
        },
        {
          "name": "Nicoderm Patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": null,
      "start_date": "1998-10",
      "completion_date": "2001-09",
      "has_results": false,
      "last_update_posted_date": "2009-01-21",
      "last_synced_at": "2026-09-27T20:33:12.226Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00018278"
    },
    {
      "nct_id": "NCT01030692",
      "title": "Rivastigmine and Huperzine A as Treatments for Cocaine Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Dependence",
        "Cocaine Addiction",
        "Cocaine Abuse",
        "Substance Abuse"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 3 mg",
          "type": "DRUG"
        },
        {
          "name": "Huperzine A 0.4 mg",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 6 mg",
          "type": "DRUG"
        },
        {
          "name": "Huperzine A 0.8 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2009-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2015-01-27",
      "last_synced_at": "2026-09-27T20:33:12.226Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01030692"
    }
  ]
}